Protein arginine methyltransferase 5 mediates arginine symmetric dimethylation of influenza A virus PB2 and supports viral replication

• Published in: Journal of medical virology 2023-10, Vol.95 (10), p.e29171-n/a
• Main Authors: Sun, Huimin, Tu, Shaoyu, Luo, Didan, Dai, Chao, Jin, Meilin, Chen, Huanchun, Zou, Jiahui, Zhou, Hongbo
• Format: Article
• Language: English
• Subjects: influenza A virus; PB2; PRMT5; symmetric dimethylation; vRNP
• ISSN: 0146-6615; 1096-9071
• DOI: 10.1002/jmv.29171

Influenza A virus (IAV) relies on intricate and highly coordinated associations with host factors for efficient replication and transmission. Characterization of such factors holds great significance for development of anti‐IAV drugs. Our study identified protein arginine methyltransferase 5 (PRMT5) as a novel host factor indispensable for IAV replication. Silencing PRMT5 resulted in drastic repression of IAV replication. Our findings revealed that PRMT5 interacts with each protein component of viral ribonucleoproteins (vRNPs) and promotes arginine symmetric dimethylation of polymerase basic 2 (PB2). Overexpression of PRMT5 enhanced viral polymerase activity in a dose‐dependent manner, emphasizing its role in genome transcription and replication of IAV. Moreover, analysis of PB2 protein sequences across various subtypes of IAVs demonstrated the high conservation of potential RG motifs recognized by PRMT5. Overall, our study suggests that PRMT5 supports IAV replication by facilitating viral polymerase activity by interacting with PB2 and promoting its arginine symmetric dimethylation. This study deepens our understanding of how IAV manipulates host factors to facilitate its replication and highlights the great potential of PRMT5 to serve as an anti‐IAV therapeutic target.